LH
LabcorpNYSEHealth CareDiagnostics & ResearchSnapshot 2026-05-08
As of May 8, 2026, LH has a composite score of 25.9, categorized with a signal label of "mild favorable." This score is influenced by a medium confidence level of 77.0 and reflects strengths in management (63.8) and valuation (64.1), while facing challenges from macro factors such as labor and rates. The analysis is provisional, indicating that the scores may change as new information becomes available.
Price
Daily closes from AlphaVantage. Earnings/event dots are placed inline.
Factor signals
Read top-to-bottom: thesis (is this a strong company over a 1–3 year hold), watch flags (has something changed worth re-reading), and position context (how violent might the path be). Each pill is a parallel diagnostic — never aggregated into a single score.
Thesis
— is this a strong company over a 1–3 year hold?Why this rank
- Direction share0.95
- Slope (norm)-0.37
- Bonus0.00
Why this rank
Trailing four: 2024-Q3, 2025-Q1, 2025-Q2, 2025-Q3
Why this rank
Watch
— has something changed worth re-reading?Why this setup
EPS estimate $4.74 → $4.78 (+0.9% / 30d). 7 raised, 3 cut, 14 covering analysts.
0 upgrades, 0 downgrades / 30d. 75% of analysts rate Buy.
1 PT revisions / 30d. Avg target 30.5% above current price.
0 positive, 0 negative / 30d.
F4 · Management deep-dive — recent events, stated priorities, guidance track record
Recent 8-K events
7 material events in the last 24 months — top 5 listed below.
- 2026-02-09LH — President transitionimpact 0.45
- 2025-12-15LH — President transitionimpact 0.38
- 2026-03-20LH — credit agreementimpact 0.35
- 2026-04-09LH — dividend updateimpact 0.29
- 2026-03-20LH — capital allocation — Creation of a Direct Financial Obligation or an Obligation under an Off-Balan…impact 0.27
Stated priorities
3 priorityies extracted from earnings transcripts (as of 2026-05-08).
- 1.Increase 2026 Adjusted EPS Guidancegrowthbehind5% progress
4/30: “Labcorp raised its full year Adjusted EPS guidance to $18.03 at the midpoint.”
Why this status
Stated in 2 of last 2 quarters. Adjusted EPS guidance was raised from $17.9 to $18.03 at the midpoint, reflecting a $0.13 increase. The trajectory shows limited progress as the status remains behind.
- 2.Update 2026 Revenue Guidancegrowthbehind5% progress
4/30: “Labcorp updated 2026 full year revenue guidance to $14.65 to $14.8 billion.”
Why this status
Stated in 2 of last 2 quarters. Revenue guidance was updated from $14.61-$14.79 billion to $14.65-$14.8 billion, reflecting a slight increase. The trajectory shows limited progress as the status remains behind.
- 3.Provide 2026 Free Cash Flow Guidancecapital allocationmixed35% progress
2/17: “Provided Free Cash Flow guidance of $1.24 billion to $1.36 billion.”
Why this status
Newly stated in 2025-Q4. Free Cash Flow guidance was provided at $1.24 billion to $1.36 billion, with a midpoint growth of 7.8%. The trajectory is behind as the status remains unchanged.
Guidance track record
Insufficient guidance history for this ticker.
Position context
— how violent might the path be while I hold it?Why this risk level
Recent vol — 30d annualized 24%; 252d 23%.
Drawdown — Max 1y −15%. Bad day move −2%.
Beta to sector ETF (XLV) — 0.63 over 1y.
Liquidity — score 100/100.
Sub-scores — vol 61/100, drawdown 70/100, beta 63/100, earnings vol —.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive — historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only — describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-05-08.
What changed
The most important moves since the prior daily snapshot.
- No material changes since the prior snapshot.
No material changes since the prior snapshot.
as of 2026-05-08
Management scorecard
How management runs the business — capital, margins, balance sheet, and how reliably they guide and deliver.
What management is focused on
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
- #1
Increase 2026 Adjusted EPS Guidance
GrowthNew since 2026-05-04Labcorp aims to increase its 2026 Adjusted EPS guidance to reflect improved performance.
BehindStated in 2 of last 2 quarters. Adjusted EPS guidance was raised from $17.9 to $18.03 at the midpoint, reflecting a $0.13 increase. The trajectory shows limited progress as the status remains behind.
5%CEO/CFO:“Labcorp raised its full year Adjusted EPS guidance to $18.03 at the midpoint.”Multiple sourcesSource dated 2026-04-30Stated 2 of last 8 quartersFirst seen 2026-05-04Show history (2)
- 2026-Q1Multiple sources
“Labcorp raised its full year Adjusted EPS guidance to $18.03 at the midpoint.”
- 2025-Q4Multiple sources
“Adjusted EPS of $17.55 to $18.25; midpoint growth of 8.9%”
- #2
Update 2026 Revenue Guidance
GrowthNew since 2026-05-04Labcorp is updating its 2026 revenue guidance to align with its performance outlook.
BehindStated in 2 of last 2 quarters. Revenue guidance was updated from $14.61-$14.79 billion to $14.65-$14.8 billion, reflecting a slight increase. The trajectory shows limited progress as the status remains behind.
5%CEO/CFO:“Labcorp updated 2026 full year revenue guidance to $14.65 to $14.8 billion.”Multiple sourcesSource dated 2026-04-30Stated 2 of last 8 quartersFirst seen 2026-05-04Show history (2)
- 2026-Q1Multiple sources
“Labcorp updated 2026 full year revenue guidance to $14.65 to $14.8 billion.”
- 2025-Q4Multiple sources
“Revenue of $14.61 billion to $14.79 billion; midpoint growth of 5.4%”
- #3
Provide 2026 Free Cash Flow Guidance
Capital allocationNew since 2026-05-04Labcorp aims to provide guidance on its free cash flow for 2026.
Behind →MixedNewly stated in 2025-Q4. Free Cash Flow guidance was provided at $1.24 billion to $1.36 billion, with a midpoint growth of 7.8%. The trajectory is behind as the status remains unchanged.
Free Cash Flow guidance of $1.24 billion to $1.36 billion35%CEO/CFO:“Provided Free Cash Flow guidance of $1.24 billion to $1.36 billion.”Multiple sourcesSource dated 2026-02-17Stated 1 of last 8 quartersFirst seen 2026-05-04Show history (1)
- 2025-Q4Multiple sources
“Provided Free Cash Flow guidance of $1.24 billion to $1.36 billion.”
How this stock is priced
Two ways to read price: against peers in the same business, and against the company's own history.
Roughly priced in line with peers.
Around its own typical valuation.
P/E over the last 5 years
71 monthly pointsHow this compares
A side-by-side read on composite, valuation, and risk versus peers.
| Stock | Composite | Valuation | Risk |
|---|---|---|---|
LH Labcorp | +26 | fair | moderate |
LLY Lilly (Eli) | +21 | full | moderate |
JNJ Johnson & Johnson | +18 | full | low |
ABBV AbbVie | +12 | fair | low |
UNH UnitedHealth Group | +24 | fair | elevated |
Risk — how this stock moves
What a normal day looks like, what a bad day looks like, and the worst the last year has thrown at it.
What could change this view
Conditional scenarios — if X happens, the score would shift by about Y points. These are not predictions.
- If health_care sector trend rises from +0.06 into 'improving' (>= +0.20)+5.0 pts
- If next-quarter guidance is cut (currently RAISED as of 2026-04-30)-16 pts
- If labor state reverses from -0.31 (negative) to +0.31 (positive)-6.8 pts
- If health_care sector trend falls from +0.06 into 'weakening' (<= -0.20)-5.0 pts
- If rates state reverses from -0.37 (negative) to +0.37 (positive)-2.9 pts
Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-04-308d agoItem 2.02
Results of Operations and Financial Condition.
earnings preannouncementneutralscore 54 - 2026-04-0929d agoItem 7.01
Regulation FD Disclosure Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced on April 9, 2026, that its Board of Directors has declared a cash dividend in the amount of $0.72 per share of common stock. The dividend will be payable on June 11, 2026, to stockholders of record as of the close of business on May 29, 2026 . A copy of the press release is furnished as Exhibit 99.1 hereto and incorporated by reference herein.
capital allocationneutralscore 26 - 2026-03-201mo agoItem 1.01
Entry into a Material Definitive Agreement. On March 20, 2026 (the “Closing Date”), Labcorp Holdings Inc. (the “Company”), as parent guarantor, and Laboratory Corporation of America Holdings (“LCAH”), as borrower, entered into a Term Loan Credit Agreement (the “Credit Agreement”) with Wells Fargo Bank, National Association (“Wells Fargo”), as administrative agent, Wells Fargo Securities, LLC, as joint lead arranger and sole bookrunner, PNC Capital Markets LLC, as joint lead arranger, PNC Bank…
capital allocationneutralscore 21 - 2026-03-201mo agoItem 2.03
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in
capital allocationnegativescore 17 - 2026-02-172mo agoItem 2.02
Results of Operations and Financial Condition
earnings preannouncementneutralscore 10
Score history
The composite score, snapshot by snapshot. The dotted line at zero separates leaning-positive from leaning-negative.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.